Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery

Author:

Shekarian Tala1ORCID,Zinner Carl P.12ORCID,Bartoszek Ewelina M.1ORCID,Duchemin Wandrille3ORCID,Wachnowicz Anna T.1ORCID,Hogan Sabrina1ORCID,Etter Manina M.1ORCID,Flammer Julia1,Paganetti Chiara1,Martins Tomas A.1ORCID,Schmassmann Philip1ORCID,Zanganeh Steven4ORCID,Le Goff Francois5ORCID,Muraro Manuele G.6ORCID,Ritz Marie-Françoise17,Phillips Darci8910ORCID,Bhate Salil S.910ORCID,Barlow Graham L.910ORCID,Nolan Garry P.10,Schürch Christian M.91011ORCID,Hutter Gregor17ORCID

Affiliation:

1. Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel, Basel, Switzerland.

2. Institute of Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland.

3. sciCORE Center for Scientific Computing, University of Basel, Basel, Switzerland.

4. Department of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, USA.

5. Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.

6. Tissue Engineering Laboratory, Department of Biomedicine, University Hospital of Basel and University of Basel, Basel, Switzerland.

7. Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.

8. Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.

9. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.

10. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

11. Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.

Abstract

A patient-tailored, ex vivo drug response platform for glioblastoma (GBM) would facilitate therapy planning, provide insights into treatment-induced mechanisms in the immune tumor microenvironment (iTME), and enable the discovery of biomarkers of response. We cultured regionally annotated GBM explants in perfusion bioreactors to assess iTME responses to immunotherapy. Explants were treated with anti-CD47, anti–PD-1, or their combination, and analyzed by multiplexed microscopy [CO-Detection by indEXing (CODEX)], enabling the spatially resolved identification of >850,000 single cells, accompanied by explant secretome interrogation. Center and periphery explants differed in their cell type and soluble factor composition, and responses to immunotherapy. A subset of explants displayed increased interferon-γ levels, which correlated with shifts in immune cell composition within specified tissue compartments. Our study demonstrates that ex vivo immunotherapy of GBM explants enables an active antitumoral immune response within the tumor center and provides a framework for multidimensional personalized assessment of tumor response to immunotherapy.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3